Education
About Us
Working with TipRanks
Follow Us
PMV Pharmaceuticals (PMVP)
NASDAQ:PMVP
PMVP Stock Chart & Stats
Day’s Range― - ―
52-Week Range$0.82 - $2.26
Previous CloseN/A
Volume81.53K
Average Volume (3M)126.07K
Market Cap
$45.18M
Enterprise Value-$93.55M
Total Cash (Recent Filing)$361.42M
Total Debt (Recent Filing)$0.00
Price to Earnings (P/E)―
Beta1.79
Next Earnings
May 08, 2025EPS Estimate
-0.37Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)-1.14
Shares Outstanding51,933,605
10 Day Avg. Volume162,903
30 Day Avg. Volume126,072
Financial Highlights & Ratios
PEG RatioN/A
Price to Book (P/B)N/A
Price to Sales (P/S)N/A
Price to Cash Flow (P/CF)-1.00
P/FCF Ratio0.00
Enterprise Value/Market Cap-2.07
Enterprise Value/RevenueN/A
Enterprise Value/Gross ProfitN/A
Enterprise Value/Ebitda1.12
Forecast
1Y Price Target
$5.00Price Target Upside474.71% Upside
Rating ConsensusModerate Buy
Number of Analyst Covering2
---
PMV Pharmaceuticals News
PremiumCompany Announcements
PMV Pharmaceuticals Reports Progress in Clinical Trials
---
Bulls Say, Bears Say
Bulls Say
Clinical Trials ProgressEnrollment into the pivotal Ph2 portion of the PYNNACLE trial evaluating rezatapopt monotherapy in TP53 Y220C and KRAS WT advanced solid tumors remains on track.
Financial PositionPMV ended 2024 with $183.3M in cash, which should fund operations to end-2026.
Bears Say
Clinical Trial RisksRisks include negative PC14586 clinical data, delays in moving candidates into advanced trials, and setbacks in later-stage studies.
Trial DiscontinuationThe Keytruda combo arm of PYNNACLE was discontinued due to limited clinical benefit.
---
Ownership Overview
3.02% Insiders
8.60% Mutual Funds
53.91% Other Institutional Investors
30.30% Public Companies and
Individual Investors
Risk Analysis
Main Risk Category
Tech & InnovationRisks related to the company’s reliance on technology and ability to make innovative products
Website Traffic
Sorry, No Data AvailableThere is no website visitor data available for this stock.
---
PMVP FAQ
What was PMV Pharmaceuticals’s price range in the past 12 months?
PMV Pharmaceuticals lowest stock price was $0.82 and its highest was $2.26 in the past 12 months.
What is PMV Pharmaceuticals’s market cap?
PMV Pharmaceuticals’s market cap is $45.18M.
When is PMV Pharmaceuticals’s upcoming earnings report date?
PMV Pharmaceuticals’s upcoming earnings report date is May 08, 2025 which is in 25 days.
How were PMV Pharmaceuticals’s earnings last quarter?
PMV Pharmaceuticals released its earnings results on Mar 03, 2025. The company reported -$0.45 earnings per share for the quarter, missing the consensus estimate of -$0.388 by -$0.062.
Is PMV Pharmaceuticals overvalued?
According to Wall Street analysts PMV Pharmaceuticals’s price is currently Undervalued.
Does PMV Pharmaceuticals pay dividends?
PMV Pharmaceuticals does not currently pay dividends.
What is PMV Pharmaceuticals’s EPS estimate?
PMV Pharmaceuticals’s EPS estimate is -0.37.
How many shares outstanding does PMV Pharmaceuticals have?
PMV Pharmaceuticals has 51,933,605 shares outstanding.
What happened to PMV Pharmaceuticals’s price movement after its last earnings report?
PMV Pharmaceuticals reported an EPS of -$0.45 in its last earnings report, missing expectations of -$0.388. Following the earnings report the stock price went down -3.65%.
Which hedge fund is a major shareholder of PMV Pharmaceuticals?
Currently, no hedge funds are holding shares in PMVP
---
PMV Pharmaceuticals Stock Smart Score
Neutral
1
2
3
4
5
6
7
8
9
10
Analyst Consensus
Moderate Buy
Average Price Target:
$5.00 (474.71% Upside)
$5.00 (474.71% Upside)
Hedge Fund Trend
Decreased
By 11.5K Shares
Last Quarter.
Last Quarter.
Crowd Wisdom
Very Negative
Last 7 Days ▼ 1.4%
Last 30 Days ▼ 9.3%
Last 30 Days ▼ 9.3%
News Sentiment
Neutral
Bullish news 59%
Bearish news 100%
Bearish news 100%
Technicals
SMA
Negative
20 days / 200 days
Momentum
-44.81%
12-Months-Change
Fundamentals
Return on Equity
-29.23%
Trailing 12-Months
Asset Growth
-24.14%
Trailing 12-Months
Company Description
PMV Pharmaceuticals
PMV Pharmaceuticals, Inc., a precision oncology company, engages in the discovery and development of small molecule and tumor-agnostic therapies for p53 mutations in cancer. The company's lead product candidate is PC14586, a small molecule that corrects a p53 protein containing the Y220C mutation and restores wild-type p53 function. It is also developing mutant p53 programs, including Wild-type p53 Induced-Phosphatase, R282W, and R273H, as well as other p53 hotspot mutations. The company was formerly known as PJ Pharmaceuticals, Inc. and changed its name to PMV Pharmaceuticals, Inc. in July 2013. PMV Pharmaceuticals, Inc. was incorporated in 2013 and is headquartered in Cranbury, New Jersey.
---
PMVP Stock 12 Month Forecast
Average Price Target
$5.00
▲(474.71% Upside)
Technical Analysis
Fate Therapeutics
―
Karyopharm Therapeutics
―
Marinus
―
Krystal Biotech
―
Precision BioSciences
―
Best Analysts Covering PMVP
1 Year
1 Year Success Rate
0/7 ratings generated profit
1 Year Average Return
-36.37%
reiterated a buy rating last month
Copying Yaron Werber's trades and holding each position for 1 Year would result in 0.00% of your transactions generating a profit, with an average return of -36.37% per trade.
---